Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Myeloid 2Lymphoid 2Genitourinary 2Gastrointestinal 2CNS 2

Conditions

Sarcoma 3Central Nervous System Neoplasms 3Wilms Tumor 2Thyroid Neoplasms 2Thyroid Diseases 2Thyroid Cancer, Papillary 2Thoracic Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms by Site 2Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Lung Diseases 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Head and Neck Neoplasms 2Glioma 2Ependymoma 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Cyclophosphamide 10Temozolomide 8X-Rays 7Specimen Handling 7Irinotecan 7Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Filgrastim 6Carboplatin 5Biopsy 5fludarabine 4Nuclear Medicine Department, Hospital 4olaparib 3fludarabine phosphate 3etoposide phosphate 3dinutuximab 3Zoledronic Acid 3Oxaliplatin 3Nivolumab 3Ifosfamide 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Etoposide 3Docetaxel 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2lorukafusp alfa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Osteosarcoma × selpercatinib × CNS × Clear all
NCT04320888 2026-05-27

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1 enrolled 3 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03155620 2026-05-05

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡